USNA
USANA Health Sciences, Inc.
NYSEUSDEQUITY
Consumer Defensive
DELAYED
Last price
13.55
▲ 0.37 (2.81%)
MARKET · —
Price
Open
13.13
Prev close
13.18
Day high
13.55
Day low
13.13
Volume
148.69K
Market cap
$250.36M
P/E (TTM)
—
52W range
12.57 – 32.29
Trailing performance
Returnvs SPY
1W
+1.35%
+2.7%
1M
-35.23%
-39.0%
3M
-26.99%
-30.1%
6M
-37.47%
-48.5%
YTD
-30.97%
-43.3%
1Y
-56.46%
-76.5%
3Y
-78.78%
-153.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$250.36M
Enterprise value$126.46M
Revenue (TTM)$913.36M
Gross profit$707.36M
EBITDA$73.92M
Net income$-22.16M
EPS (TTM)$-1.18
Free cash flow$49.13M
Total cash$168.56M
Total debt$0
Book value / share$28.51
Shares outstanding18.48M
Float9.93M
Short % of float6.32%
Dividend yield—
Beta (5Y)0.73
Valuation & profitability ratios
Trailing P/E—
Forward P/E7.66
PEG ratio1.04
Price / sales—
Price / book0.48
EV / revenue0.14
EV / EBITDA1.71
Gross margin77.45%
Operating margin4.09%
Profit margin-2.43%
Return on equity-5.06%
Return on assets3.61%
Debt / equity—
Current ratio2.66
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $925.26M | $854.50M | $921.01M | $998.60M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | $10.76M | $42.03M | $63.79M | $69.35M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | $10.76M | $42.03M | $63.79M | $69.35M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.43 | -0.07 | -116.3% |
| Mar 2026 | 0.44 | 0.61 | +38.6% |
| Dec 2025 | 0.41 | 0.60 | +46.3% |
| Sep 2025 | -0.15 | -0.15 | 0.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.11 | 1 | $219.02M | +2.5% |
| Next quarter | 0.11 | 1 | $217.06M | -4.0% |
| Current year | 0.76 | 1 | $909.57M | -1.7% |
| Next year | 1.77 | 1 | $949.84M | +4.4% |
Analyst targets & ownership
Mean target$25.00
High target$25.00
Low target$25.00
Implied upside84.50%
Analyst count1
ConsensusNONE
Strong buy / Buy0 / 0
Hold0
Sell / Strong sell0 / 0
Held by insiders40.88%
Held by institutions63.15%
Institutions holding206
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+26.73K
Net buying
Buy transactions
24
69.35K shares
Sell transactions
11
42.62K shares
Net transactions
+35
Buys less sells
Sell : buy shares
0.6 : 1
Mixed
Insider-held shares
7.55M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 24, 26 | BENEDICT PETER Chief Technology Officer |
— | 598 | — | Direct |
| Jul 24, 26 | ARMSTRONG KATHRYN MICHELLE PH.D. Officer |
— | 1.17K | — | Direct |
| Jul 23, 26 | WINSSINGER FREDERIC J. Director |
— | 1.63K | — | Direct |
| Jul 23, 26 | NIXON J SCOTT Director |
— | 1.63K | — | Direct |
| Jul 23, 26 | FULLER GILBERT A Director |
— | 1.63K | — | Direct |
| Jul 23, 26 | PELOSI PEGGIE J Director |
— | 1.63K | — | Direct |
| Jul 23, 26 | FLEMING JOHN TURMAN Director |
— | 1.63K | — | Direct |
| Jul 23, 26 | DING XIA Director |
— | 1.63K | — | Direct |
| Jul 23, 26 | WOOD TIMOTHY E Director |
— | 1.63K | — | Direct |
| Jun 16, 26 | NEIDIG BRENT LOWELL Officer |
SELL | 5.00K | $97.30K | Direct |
| Jun 15, 26 | NEIDIG BRENT LOWELL Officer |
SELL | 2.51K | $50.47K | Direct |
| Jun 8, 26 | JONES PAUL A Officer |
SELL | 5.56K | $102.88K | Direct |
| Jun 1, 26 | FLEMING JOHN TURMAN Director |
SELL | 2.45K | $43.93K | Direct |
| May 28, 26 | JONES PAUL A Officer |
SELL | 6.81K | $129.11K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BROWN JIM H |
Chief Executive Officer | 16.93K | Conversion of Exercise of derivative security |
DING XIA |
Director | 8.28K | Conversion of Exercise of derivative security |
GUEST KEVIN G |
Chief Executive Officer | 45.38K | Conversion of Exercise of derivative security |
MULHAM DAVID MULHAM |
Officer | 8.39K | Sale |
NIXON J SCOTT |
Director | 11.45K | Conversion of Exercise of derivative security |
NOOT WALTER |
Chief Operating Officer | 9.26K | Conversion of Exercise of derivative security |
PELOSI PEGGIE J |
Director | 6.06K | Conversion of Exercise of derivative security |
WENTZ MYRON W |
Beneficial Owner of more than 10% of a Class of Security | — | Stock Gift |
WINSSINGER FREDERIC J. |
Director | 9.73K | Conversion of Exercise of derivative security |
WOOD TIMOTHY E |
Director | 11.84K | Conversion of Exercise of derivative security |
Moving averages & technicals
SMA 10
13.47
+0.60% from price
SMA 20
16.91
-19.87% from price
SMA 50
19.32
-29.88% from price
SMA 100
18.93
-28.41% from price
SMA 200
19.38
-30.07% from price
EMA 12
14.53
-6.73% from price
EMA 26
16.65
-18.63% from price
EMA 50
18.05
-24.91% from price
RSI (14)
30.0
Oversold
MACD (12,26,9)
-2.12
Hist -0.26
ATR (14)
1.26
9.27% of price
Realised vol 30D
127.9%
Annualised
Bollinger upper
25.36
20, 2σ
Bollinger lower
8.46
20, 2σ
50 / 200 cross
Death
19.32 vs 19.38
Trend bias
Below 200
-30.07%
Risk profile
Beta vs SPY
1.22
More volatile than market
Correlation to SPY
0.27
Largely independent
Realised vol 30D
127.9%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-60.1%
Peak to trough
Max drawdown 5Y
-87.6%
Peak to trough
ATR 14
1.26
9.27% of price
Beta (reported)
0.73
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
3.88
Put-heavy session
Put / call open interest
2.02
Positioning, not flow
Max pain
15.00
+10.7% from spot
ATM implied vol
98.6%
Nearest strike to spot
Skew (10% OTM)
-143.6%
Calls bid over puts
Call volume
8
Contracts, this expiry
Put volume
31
Contracts, this expiry
Heaviest call OI
15.00
34 contracts
Heaviest put OI
12.50
69 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
1 Oversold Stock Set for a Comeback and 2 We Avoid
StockStory · 4d ago
USANA Introduces 3-in-1 Protein, Creatine, and Electrolyte Drink Mix
PR Newswire · 5d ago
3 Small-Cap Stocks We Find Risky
StockStory · 6d ago
5 Must-Read Analyst Questions From USANA’s Q2 Earnings Call
StockStory · 10d ago
USANA (USNA) Q2 2026 Earnings Call Transcript
Motley Fool · 11d ago
3 Russell 2000 Stocks We Find Risky
StockStory · 12d ago
Why Usana Health Sciences Stock Plummeted This Week
Motley Fool · 13d ago
USANA Health Sciences Q2 Earnings Call Highlights
MarketBeat · 13d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.